N1-(3-chlorophenyl)-2-(1,3,4-trimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)hydrazine-1-carboxamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N1-(3-chlorophenyl)-2-(1,3,4-trimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)hydrazine-1-carboxamide
• 英文别名: 1-(3-chlorophenyl)-3-[(1,3,4-trimethylpyrazolo[3,4-b]pyridin-6-yl)amino]urea
• 化学式: C₁₆H₁₇ClN₆O
• 分子量: 344.8
• InChiKey: SWTNQTGSOCFDMA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  83.9
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Pharmaceutical composition for treatment of disease due to vascular constriction or vasodilation
  申请人：Nakade Shinij

  公开号：US20060148844A1

  公开（公告）日：2006-07-06

  A therapeutic and/or preventing agent for a disease due to vascular constriction or vasodilation comprising a EDG-5 modulator. Since EDG-5 modulator specifically binds EDG-5 and shows antagonistic or agonistic action, EDG-5 antagonist is useful for treating and/or preventing for a disease due to vascular constriction, for example, cerebrovascular spasmodic disorder after subarachnoid hemorrhage or stroke, cardiovasucular spasmodic disorder, hypertension, renal disease, cardiac infarction, cardiac angina, arrhythmia, facilitation of the portal blood pressure involved in liver cirrhosis, varicosity involved in liver cirrhosis and the like, or EDG-5 agonist is useful for treating and/or preventing for a disease due to vasodilation of blood vessels, for example, chronic headache (such as migraine, tension-type headache, mixed-type headache thereof, or migrainous neuralgia), haemorrhoid, congestive disorder and the like.

  一种治疗和/或预防由血管收缩或扩张引起的疾病的药物，包括EDG-5调节剂。由于EDG-5调节剂专门结合EDG-5并显示拮抗或激动作用，因此EDG-5拮抗剂可用于治疗和/或预防由血管收缩引起的疾病，例如蛛网膜下出血或中风后的脑血管痉挛性障碍，心血管痉挛性障碍，高血压，肾脏疾病，心肌梗死，心绞痛，心律失常，促进涉及肝硬化的门静脉血压，涉及肝硬化的静脉曲张等，或EDG-5激动剂可用于治疗和/或预防由血管扩张引起的疾病，例如慢性头痛（如偏头痛，紧张型头痛，混合型头痛或偏头痛性神经痛），痔疮，充血性疾病等。
• Remedies for diseases caused by vascular contraction or dilation
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP2508204A2

  公开（公告）日：2012-10-10

  A therapeutic and/or preventing agent for a disease due to vascular constriction or vasodilation comprising a EDG-5 modulator. Since EDG-5 modulator specifically binds EDG-5 and shows antagonistic or agonistic action, EDG-5 antagonist is useful for treating and/or preventing for a disease due to vascular constriction, for example, cerebrovascular spasmodic disorder after subarachnoid hemorrhage or stroke, cardiovasucular spasmodic disorder, hypertension, renal disease, cardiac infarction, cardiac angina, arrhythmia, facilitation of the portal blood pressure involved in liver cirrhosis, varicosity involved in liver cirrhosis and the like, or EDG-5 agonist is useful for treating and/or preventing for a disease due to vasodilation of blood vessels, for example, chronic headache (such as migraine, tension-type headache, mixed-type headache thereof, or migrainous neuralgia), haemorrhoid, congestive disorder and the like.

  一种治疗和/或预防因血管收缩或血管扩张引起的疾病的药物，包括 EDG-5 调节剂。由于 EDG-5 调节剂特异性结合 EDG-5，并显示出拮抗或激动作用，EDG-5 拮抗剂可用于治疗和/或预防血管收缩引起的疾病，例如蛛网膜下腔出血或中风后的脑血管痉挛性疾病、心血管痉挛性疾病、高血压、肾病、心肌梗塞、心绞痛、心律失常、EDG-5激动剂可用于治疗和/或预防因血管扩张引起的疾病，例如慢性头痛（如偏头痛、紧张型头痛、混合型头痛或偏头痛性神经痛）、痔疮、充血性疾病等。
• REMEDIES FOR DISEASES CAUSED BY VASCULAR CONTRACTION OR DILATION
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1522314B1

  公开（公告）日：2014-03-05
• US8765783B2
  申请人：——

  公开号：US8765783B2

  公开（公告）日：2014-07-01